General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination

Author(s): Aline Baldo, Eric van den Akker, Hans E. Bergmans, Filip Lim, Katia Pauwels

Journal Name: Current Gene Therapy

Volume 13 , Issue 6 , 2013

Become EABM
Become Reviewer
Call for Editor


This introductory paper gathers general considerations on the biosafety of virus-derived vectors that are used in human gene therapy and/or vaccination. The importance to assess the potential risks for human health and the environment related to the use of genetically modified organisms (GMO) in this case genetically modified viral vectors is highlighted by several examples. This environmental risk assessment is one of the requirements within the European regulatory framework covering the conduct of clinical trials using GMO. Risk assessment methodologies for the environmental risk assessment of genetically modified virus-derived vectors have been developed.

Keywords: Biosafety, environmental risk assessment, gene therapy, genetically modified organisms, vaccination, viral vectors.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 06 November, 2013
Page: [385 - 394]
Pages: 10
DOI: 10.2174/15665232113136660005

Article Metrics

PDF: 111